RADX Radiopharm Theranostics Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1949257 · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-06-30 | FY2024*2024-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $3.63M | $299,228 |
| Cost of revenue | $3.59M | — |
| Gross profit | $39,276 | $299,228 |
| R&D expense | $27.52M | $23.09M |
| SG&A expense | $14.64M | $13.04M |
| Operating income | -$38.17M | -$47.21M |
| Interest expense | $65,300 | $642,888 |
| Pretax income | -$38.24M | -$47.85M |
| Income tax | $103,292 | $96,364 |
| Net income | -$38.34M | -$47.95M |
| EBITDA | -$35.58M | -$44.08M |
| EPS (basic) | -1.76 | -12.41 |
| EPS (diluted) | -1.76 | -12.41 |
| Weighted avg. shares (diluted) | 2.08B | 386.46M |
| Balance sheet | ||
| Cash & equivalents | $29.12M | $18.58M |
| Receivables | $10.40M | $987,413 |
| Current assets | $39.85M | $22.85M |
| PP&E, netmay include right-of-use assets (IFRS) | $53,466 | $60,797 |
| Intangibles | $46.57M | $49.09M |
| Total assets | $86.48M | $72.04M |
| Current liabilities | $14.93M | $17.58M |
| Total liabilities | $43.61M | $44.68M |
| Shareholders' equity | $44.79M | $28.12M |
| Cash flow statement | ||
| Operating cash flow | -$36.65M | -$22.98M |
| Investing cash flow | $1.77M | -$320,000 |
| Financing cash flow | $45.43M | $30.20M |
| Depreciation & amortization | $2.60M | $3.13M |
| Stock-based compensation | $1.90M | $2.64M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.